Stallergenes forges $198M pact for allergy R&D

France's Stallergenes has inked a deal worth up to $198 million with biotech DBV Technologies, partnering with the company to develop a treatment for birch allergy. Under the agreement, DBV will apply its Viaskin drug delivery platform to one of Stallergenes' preclinical candidates, and the company is eligible for royalties if the resulting therapy hits the market. More

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.